Oppenheimer comes to the defense of Questcor (QCOR -1.5%), which was crushed yesterday after...


Oppenheimer comes to the defense of Questcor (QCOR -1.5%), which was crushed yesterday after arriving on TheStreetSweeper's crosshairs. In reiterating an Outperform, Oppenheimer says there is no evidence Questcor promotes its Acthar drug for off-label uses. However, the market continues to have its concerns; shares are selling off again today, giving back yesterday's AH gains in the process.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs